Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Retrospective Audit of the Use of Next-Generation Sequencing in the Management of Myelofibrosis Patients in North London Hospitals

Ke Xu, MD MRCP, FRCPath, Andrew Wilson, MA, MSc, PhD MRCP, FRCPath, Elisabeth P. Nacheva, MD PhD FRCPath, Temenuzhka Boneva, MD PhD, Rajeev Gupta, MB.ChB, PhD FRCP, FRCPath

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-133779

Published: 2020

Journal Articles

Absence of Damaging Effects of Stem Cell Donation in Unrelated Donors Assessed By FISH and Gene Variance Screening

Elisabeth P. Nacheva, MD PhD, Trudy Ahyee, C Navarette, Juanah Addada, MDPhDFRCP, Rachel Pawson, Richard Syzdlo, PhD, Stephen Mackinnon, MD, Bronwen E. Shaw, MD PhD, J. Alejandro Madrigal, MDPhDDSc,FRCP,FRCPath

Blood (2019) 134 (Supplement_1): 4474.

https://doi.org/10.1182/blood-2019-131931

Published: 2019

Journal Articles

Molecular Karyotyping Combined with FISH Offers an Alternative to Chromosome Banding Analysis for Diagnostic Evaluation of Genome Complexity in Acute Myeloid Leukemia

A Borsatti, Elisabeth P. Nacheva, MD PhD

Blood (2019) 134 (Supplement_1): 5188.

https://doi.org/10.1182/blood-2019-131983

Published: 2019

Journal Articles

Synthetic Lethal Screening Identifies CHK1 Inhibition As an Exploitable Vulnerability in EZH2 Deficient T-ALL

Theresa E. Leon, PhD MSc, BSc, Tanya Rapoz-D'Silva, BSc, MSc, Sunniyat Rahman, MBiochem, DIC, PhD, Michael Magnussen, BSc, MSc, Nadine Farah, MBBChir, MA, MRCP, FRCPath, Jose A. Guerra-Assunção, BSc, PhD, Rajeev Gupta, MB.ChB, PhD FRCP, FRCPath, Elisabeth P. Nacheva, MD PhD, Javier Herrero, PhD, David C. Linch, FRCP, Marc R. Mansour, MD PhD FRCPath

Blood (2017) 130 (Supplement 1): 1325.

https://doi.org/10.1182/blood.V130.Suppl_1.1325.1325

Published: 2017

Journal Articles

Imbalances of Chromosome 21 in MDS/AML Include Cryptic Deletions but NOT RUNX1 Amplifications.

Katya Gancheva, Diana Brazma, Dr, Nahid Zarein, Julie Howard-Reeves, Phaidra Partheniou, Colin Grace, PhD, Elisabeth P. Nacheva, MD, PhD

Blood (2012) 120 (21): 2561.

https://doi.org/10.1182/blood.V120.21.2561.2561

Published: 2012

Journal Articles

MOLECULAR Karyotyping In CLL - COST Neutral Alternative to FISH SCREENING for Detection of Clinically Relevant Genome Imbalances,

Eleni Tsogka, Diana Brazma, Dr, Julie Howard-Reeves, Colin Grace, PhD, Elisabeth P. Nacheva, MD, PhD

Blood (2011) 118 (21): 3561.

https://doi.org/10.1182/blood.V118.21.3561.3561

Published: 2011

Journal Articles

Are CML Lymphoid Blast Crisis and Ph Positive ALL Genomically Indistinguishable?

Colin Grace, PhD, Elisabeth P Nacheva, MD, PhD

Blood (2010) 116 (21): 4464.

https://doi.org/10.1182/blood.V116.21.4464.4464

Published: 2010

Journal Articles

A Cell Line SYRMO Derived From AML with EVI 1 Rearrangements Following Imatinib Mesylate Therapy for Chronic Myeloid Leukaemia

Panagiotis Kottaridis, Diana Brazma, Julie Howard-Reeves, Helen Mazzullo, Elisabeth P Nacheva, MD, PhD

Blood (2010) 116 (21): 4470.

https://doi.org/10.1182/blood.V116.21.4470.4470

Published: 2010

Journal Articles

Sensitivity to Imatinib In BCR-ABL1-Positive Chronic Myeloid Leukemia Cells Depends on the Presence of Normal ABL1.

Yashodhara Dasgupta, Anna Virgili, Mateusz Koptyra, Elisabeth P. Nacheva, MD, PhD, Tomasz Skorski, MD, PhD

Blood (2010) 116 (21): 3405.

https://doi.org/10.1182/blood.V116.21.3405.3405

Published: 2010

Journal Articles

Deletions of the Normal ABL1 at the Non-Translocated Chromosome 9 in CML Associated with TKI Resistance.

Anna Virgili, Diana Brazma, Dr, Colin Grace, PhD, Elisabeth P Nacheva, MD, PhD, FRCPath

Blood (2009) 114 (22): 3254.

https://doi.org/10.1182/blood.V114.22.3254.3254

Published: 2009

Journal Articles

Philadelphia Negative BCR/ABL1 Positive CML: FISH Mapping and aCGH Reveal Breakpoint Hotspots.

Anna Virgili, Diana Brazma, MD, Colin Grace, PhD, Anastasios Chanalaris, PhD, Alistair Reid, PhD, Jane F. Apperley, MD, PhD, Elisabeth P. Nacheva, MD, PhD

Blood (2007) 110 (11): 2924.

https://doi.org/10.1182/blood.V110.11.2924.2924

Published: 2007

Journal Articles

Bi-Allelic Involvement in AML: Examples of 16q Aberrations in Two Cases.

Julie Howard, Diana Brazma, Beverly Vaughan, Elisabeth P. Nacheva, MD PhD FRCPath

Blood (2006) 108 (11): 4459.

https://doi.org/10.1182/blood.V108.11.4459.4459

Published: 2006

NARROW

A Retrospective Audit of the Use of Next-Generation Sequencing in the Management of Myelofibrosis Patients in North London Hospitals

Absence of Damaging Effects of Stem Cell Donation in Unrelated Donors Assessed By FISH and Gene Variance Screening

Molecular Karyotyping Combined with FISH Offers an Alternative to Chromosome Banding Analysis for Diagnostic Evaluation of Genome Complexity in Acute Myeloid Leukemia

Synthetic Lethal Screening Identifies CHK1 Inhibition As an Exploitable Vulnerability in EZH2 Deficient T-ALL

Imbalances of Chromosome 21 in MDS/AML Include Cryptic Deletions but NOT RUNX1 Amplifications.

MOLECULAR Karyotyping In CLL - COST Neutral Alternative to FISH SCREENING for Detection of Clinically Relevant Genome Imbalances,

Are CML Lymphoid Blast Crisis and Ph Positive ALL Genomically Indistinguishable?

A Cell Line SYRMO Derived From AML with EVI 1 Rearrangements Following Imatinib Mesylate Therapy for Chronic Myeloid Leukaemia

Sensitivity to Imatinib In BCR-ABL1-Positive Chronic Myeloid Leukemia Cells Depends on the Presence of Normal ABL1.

Deletions of the Normal ABL1 at the Non-Translocated Chromosome 9 in CML Associated with TKI Resistance.

Philadelphia Negative BCR/ABL1 Positive CML: FISH Mapping and aCGH Reveal Breakpoint Hotspots.

Bi-Allelic Involvement in AML: Examples of 16q Aberrations in Two Cases.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only